A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX4032 in Patients With Solid Tumors

Trial Profile

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX4032 in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Plexxikon
  • Most Recent Events

    • 18 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 12 Oct 2015 Results of extension cohort (n=21; assessing objective tumour response in patients with colorectal cancer and BRAF + V600E mutations) published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top